Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines?
The evolution of crystal engineering into a form of supramolecular synthesis is discussed in the context of problems and opportunities in the pharmaceutical industry. Specifically, it has become clear that a wide array of multiple component pharmaceutical phases, so called pharmaceutical co-crystals...
Gespeichert in:
| Veröffentlicht in: | Chemical communications (Cambridge, England) England), 2004-09 (17), p.1889-1896 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1896 |
|---|---|
| container_issue | 17 |
| container_start_page | 1889 |
| container_title | Chemical communications (Cambridge, England) |
| container_volume | |
| creator | Almarsson, Orn Zaworotko, Michael J |
| description | The evolution of crystal engineering into a form of supramolecular synthesis is discussed in the context of problems and opportunities in the pharmaceutical industry. Specifically, it has become clear that a wide array of multiple component pharmaceutical phases, so called pharmaceutical co-crystals, can be rationally designed using crystal engineering, and the strategy affords new intellectual property and enhanced properties for pharmaceutical substances. |
| doi_str_mv | 10.1039/b402150a |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66837017</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>66837017</sourcerecordid><originalsourceid>FETCH-LOGICAL-c391t-da70b7d09823ce46d5513559f9d4ba2096cc73f7e7475bc9ad00c52d176153a43</originalsourceid><addsrcrecordid>eNpdUE1LAzEQDaLYWgV_geQkXlaTJtlsTiL1EwpeFLwt2exsG-lu1iSr9C_4q01pRTCXycy8eTPvIXRKySUlTF1VnEypIHoPjSnLeSZ48ba_-QuVScbFCB2F8E7So6I4RCMqGCeiUGP0PfPrEPUKQ7ewHYC33QK7BsclYOPa3gUbres2pX6pfasNDNGaNJDSAOES37r_HeMys2UN2EPvIUAXscYdfOFexyWODtu29-4TatxCbU3aHK6P0UGTRuBkFyfo9f7uZfaYzZ8fnmY388wwRWNWa0kqWRNVTJkBntdCJJ1CNarmlZ4SlRsjWSNBcikqo3RNiBHTmso8ydacTdD5ljdd8DFAiGVrg4HVSnfghlDmecEkoTIBL7ZA410IHpqy97bVfl1SUm58L399T9CzHedQJUV_wJ3R7Aes6X_h</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>66837017</pqid></control><display><type>article</type><title>Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines?</title><source>Royal Society of Chemistry Journals Archive (1841-2007)</source><source>MEDLINE</source><source>Royal Society Of Chemistry Journals 2008-</source><source>Alma/SFX Local Collection</source><creator>Almarsson, Orn ; Zaworotko, Michael J</creator><creatorcontrib>Almarsson, Orn ; Zaworotko, Michael J</creatorcontrib><description>The evolution of crystal engineering into a form of supramolecular synthesis is discussed in the context of problems and opportunities in the pharmaceutical industry. Specifically, it has become clear that a wide array of multiple component pharmaceutical phases, so called pharmaceutical co-crystals, can be rationally designed using crystal engineering, and the strategy affords new intellectual property and enhanced properties for pharmaceutical substances.</description><identifier>ISSN: 1359-7345</identifier><identifier>EISSN: 1364-548X</identifier><identifier>DOI: 10.1039/b402150a</identifier><identifier>PMID: 15340589</identifier><language>eng</language><publisher>England</publisher><subject>Acids - chemistry ; Amides - chemistry ; Carboxylic Acids - chemistry ; Chemistry, Pharmaceutical - methods ; Crystallization - methods ; Crystallography ; Drug Stability ; Hydrogen Bonding ; Molecular Structure ; Organic Chemicals - chemistry ; Pharmaceutical Preparations ; Phase Transition ; Technology, Pharmaceutical - instrumentation ; Technology, Pharmaceutical - methods</subject><ispartof>Chemical communications (Cambridge, England), 2004-09 (17), p.1889-1896</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c391t-da70b7d09823ce46d5513559f9d4ba2096cc73f7e7475bc9ad00c52d176153a43</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,2818,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15340589$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Almarsson, Orn</creatorcontrib><creatorcontrib>Zaworotko, Michael J</creatorcontrib><title>Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines?</title><title>Chemical communications (Cambridge, England)</title><addtitle>Chem Commun (Camb)</addtitle><description>The evolution of crystal engineering into a form of supramolecular synthesis is discussed in the context of problems and opportunities in the pharmaceutical industry. Specifically, it has become clear that a wide array of multiple component pharmaceutical phases, so called pharmaceutical co-crystals, can be rationally designed using crystal engineering, and the strategy affords new intellectual property and enhanced properties for pharmaceutical substances.</description><subject>Acids - chemistry</subject><subject>Amides - chemistry</subject><subject>Carboxylic Acids - chemistry</subject><subject>Chemistry, Pharmaceutical - methods</subject><subject>Crystallization - methods</subject><subject>Crystallography</subject><subject>Drug Stability</subject><subject>Hydrogen Bonding</subject><subject>Molecular Structure</subject><subject>Organic Chemicals - chemistry</subject><subject>Pharmaceutical Preparations</subject><subject>Phase Transition</subject><subject>Technology, Pharmaceutical - instrumentation</subject><subject>Technology, Pharmaceutical - methods</subject><issn>1359-7345</issn><issn>1364-548X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdUE1LAzEQDaLYWgV_geQkXlaTJtlsTiL1EwpeFLwt2exsG-lu1iSr9C_4q01pRTCXycy8eTPvIXRKySUlTF1VnEypIHoPjSnLeSZ48ba_-QuVScbFCB2F8E7So6I4RCMqGCeiUGP0PfPrEPUKQ7ewHYC33QK7BsclYOPa3gUbres2pX6pfasNDNGaNJDSAOES37r_HeMys2UN2EPvIUAXscYdfOFexyWODtu29-4TatxCbU3aHK6P0UGTRuBkFyfo9f7uZfaYzZ8fnmY388wwRWNWa0kqWRNVTJkBntdCJJ1CNarmlZ4SlRsjWSNBcikqo3RNiBHTmso8ydacTdD5ljdd8DFAiGVrg4HVSnfghlDmecEkoTIBL7ZA410IHpqy97bVfl1SUm58L399T9CzHedQJUV_wJ3R7Aes6X_h</recordid><startdate>20040907</startdate><enddate>20040907</enddate><creator>Almarsson, Orn</creator><creator>Zaworotko, Michael J</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20040907</creationdate><title>Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines?</title><author>Almarsson, Orn ; Zaworotko, Michael J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c391t-da70b7d09823ce46d5513559f9d4ba2096cc73f7e7475bc9ad00c52d176153a43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Acids - chemistry</topic><topic>Amides - chemistry</topic><topic>Carboxylic Acids - chemistry</topic><topic>Chemistry, Pharmaceutical - methods</topic><topic>Crystallization - methods</topic><topic>Crystallography</topic><topic>Drug Stability</topic><topic>Hydrogen Bonding</topic><topic>Molecular Structure</topic><topic>Organic Chemicals - chemistry</topic><topic>Pharmaceutical Preparations</topic><topic>Phase Transition</topic><topic>Technology, Pharmaceutical - instrumentation</topic><topic>Technology, Pharmaceutical - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Almarsson, Orn</creatorcontrib><creatorcontrib>Zaworotko, Michael J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Chemical communications (Cambridge, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Almarsson, Orn</au><au>Zaworotko, Michael J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines?</atitle><jtitle>Chemical communications (Cambridge, England)</jtitle><addtitle>Chem Commun (Camb)</addtitle><date>2004-09-07</date><risdate>2004</risdate><issue>17</issue><spage>1889</spage><epage>1896</epage><pages>1889-1896</pages><issn>1359-7345</issn><eissn>1364-548X</eissn><abstract>The evolution of crystal engineering into a form of supramolecular synthesis is discussed in the context of problems and opportunities in the pharmaceutical industry. Specifically, it has become clear that a wide array of multiple component pharmaceutical phases, so called pharmaceutical co-crystals, can be rationally designed using crystal engineering, and the strategy affords new intellectual property and enhanced properties for pharmaceutical substances.</abstract><cop>England</cop><pmid>15340589</pmid><doi>10.1039/b402150a</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1359-7345 |
| ispartof | Chemical communications (Cambridge, England), 2004-09 (17), p.1889-1896 |
| issn | 1359-7345 1364-548X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_66837017 |
| source | Royal Society of Chemistry Journals Archive (1841-2007); MEDLINE; Royal Society Of Chemistry Journals 2008-; Alma/SFX Local Collection |
| subjects | Acids - chemistry Amides - chemistry Carboxylic Acids - chemistry Chemistry, Pharmaceutical - methods Crystallization - methods Crystallography Drug Stability Hydrogen Bonding Molecular Structure Organic Chemicals - chemistry Pharmaceutical Preparations Phase Transition Technology, Pharmaceutical - instrumentation Technology, Pharmaceutical - methods |
| title | Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T19%3A27%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Crystal%20engineering%20of%20the%20composition%20of%20pharmaceutical%20phases.%20Do%20pharmaceutical%20co-crystals%20represent%20a%20new%20path%20to%20improved%20medicines?&rft.jtitle=Chemical%20communications%20(Cambridge,%20England)&rft.au=Almarsson,%20Orn&rft.date=2004-09-07&rft.issue=17&rft.spage=1889&rft.epage=1896&rft.pages=1889-1896&rft.issn=1359-7345&rft.eissn=1364-548X&rft_id=info:doi/10.1039/b402150a&rft_dat=%3Cproquest_cross%3E66837017%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=66837017&rft_id=info:pmid/15340589&rfr_iscdi=true |